Cortes JE et al. Olutasidenib in combination with azacitidine induces durable complete remissions in patients with relapsed or refractory mIDH1 acute myeloid leukemia: A multicohort open-label phase 1/2 trial. J Hematol Oncol 2025;18(1):7. Abstract
DiNardo CD et al. Phase 1b/2 study of decitabine and venetoclax in combination with the targeted mutant IDH1 inhibitor olutasidenib for patients with relapsed/refractory AML, high risk MDS, or newly diagnosed AML not eligible for chemotherapy with an IDH1 mutation. ASH 2024;Abstract 1527.2.
Jiang B et al. Long-term follow-up of predominantly Asian patients with relapsed/refractory FLT3-mutated acute myeloid leukemia treated with gilteritinib versus salvage chemotherapy in the phase 3 COMMODORE trial. EHA 2025;Abstract S143.
Levis M et al. The combination of a FLT3-ITD, NPM1mut and an epigenetic regulatory gene mutation confers unique sensitivity to quizartinib: Analysis from the QuANTUM-First trial. EHA 2025;Abstract S140.
Levis M et al. Gilteritinib as post-transplant maintenance for AML with internal tandem duplication mutation of FLT3. J Clin Oncol 2024;42(15):1766-75. Abstract
Levis MJ et al. Measurable residual disease and posttransplantation gilteritinib maintenance for patients with FLT3-ITD-mutated AML. Blood 2025;145(19):2138-48. Abstract
Levis MJ et al. Correlation of baseline gene mutations with quizartinib efficacy in patients with FLT3-ITD–positive newly diagnosed acute myeloid leukemia in the phase 3 QuANTUM-First trial. ASH 2024;Abstract 848.
Luger S et al. Gilteritinib results in higher remission and transplant rates than midostaurin but does not increase the post-induction mutational MRD negative rate: Results of the phase 2 randomized Precog 0905 study in newly diagnosed FLT3 mutated AML. ASH 2024;Abstract 221.
Marvin-Peek J et al. A phase Ib/II study of ivosidenib with venetoclax ± azacitidine in IDH1-mutated hematologic malignancies: A 2024 update. ASH 2024;Abstract 219.
Montesinos P et al. Final results of Quiwi: A double blinded, randomized pethema trial comparing standard chemotherapy plus quizartinib versus placebo in adult patients with newly diagnosed FLT3-ITD negative AML. ASH 2024;Abstract 1512.
Montesinos P et al. Trial in progress: The phase 3, randomized, double-blind, placebo-controlled QuANTUM-Wild study of quizartinib in combination with chemotherapy and as single-agent maintenance in newly diagnosed, FLT3-ITD–negative acute myeloid leukemia. ASH 2024;Abstract 1504.3.
Mosquera Orgueira A et al. Enhanced validation of the FLT3-like gene expression signature as a predictive biomarker for quizartinib response in FLT3-ITD negative acute myeloid leukemia: Expanded cohort and extended follow-up from the Pethema Quiwi trial. ASH 2024;Abstract 1552.
Short NJ et al. Azacitidine, venetoclax, and gilteritinib in newly diagnosed and relapsed or refractory FLT3-mutated AML. J Clin Oncol 2024;42(13):1499-508. Abstract
Short NJ et al. Long-term survival outcomes and cytogenetic/molecular patterns of relapse in adults with FLT3-mutated AML receiving frontline triplet therapy with a hypomethylating agent, venetoclax and FLT3 inhibitor. ASH 2024;Abstract 220.
Stone RM et al. 10 year follow-up of CALGB 10603/Ratify: Midostaurin versus placebo plus intensive chemotherapy in newly diagnosed FLT3 mutant acute myeloid leukemia patients aged 18-60 years. ASH 2024;Abstract 218.
Wang ES et al. Time to response and overall survival in patients with mIDH1 relapsed/refractory acute myeloid leukemia treated with olutasidenib. ASH 2024;Abstract 1514.
Wang J et al. Phase 3 study of gilteritinib versus salvage chemotherapy in predominantly Asian patients with relapsed/refractory FLT3-mutated acute myeloid leukemia. Leukemia 2024;38(11):2410-8. Abstract
Yilmaz M et al. Phase I/II study of decitabine, venetoclax, and quizartinib triplet combination in FLT3-ITD mutated AML. EHA 2025;Abstract S142.